FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206425717> ?p ?o ?g. }

• W3206425717 endingPage "32.e10" @default.
• W3206425717 startingPage "32.e1" @default.
• W3206425717 abstract "Autologous stem cell transplantation (ASCT) is a standard of care for patients with chemosensitive, relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) and diffuse large B cell lymphoma (DLBCL). Whereas the clinical benefit of ASCT has traditionally been attributed solely to cytoreduction from intensive chemotherapy, ASCT has important immunogenic effects that may contribute to its antitumor efficacy and could provide a favorable immune environment for post-ASCT immune-based maintenance treatments. We previously reported clinical results of a phase II trial (ClinicalTrials.gov identifier NCT02362997) testing 8 doses of pembrolizumab maintenance therapy after ASCT for patients with R/R cHL or DLBCL. To clarify the impact of pembrolizumab on immune reconstitution, we compared the kinetics of peripheral blood immune cell recovery after ASCT for trial patients receiving pembrolizumab maintenance to those of a contemporaneous control cohort of similar patients undergoing ASCT without pembrolizumab maintenance. This study was conducted to characterize the impact of post-ASCT pembrolizumab maintenance therapy on immune reconstitution for patients with R/R DLBCL and cHL and to identify candidate biomarkers of efficacy and immune-related adverse events (irAEs). Peripheral blood (PB) mononuclear cell samples were prospectively collected at 1 to 18 months after ASCT and analyzed by flow cytometry using a panel of fluorophore-conjugated monoclonal antibodies to identify B cells, natural killer (NK) cells, and various dendritic cell (DC) and T cell subsets. A median of 5 (range, 1 to 8) post-ASCT PB samples were collected from 144 patients (59 in the pembrolizumab group and 85 in the control group). Clinical characteristics of the 2 cohorts were similar. Compared with cHL patients, DLBCL patients (all of whom received anti-CD20 monoclonal antibody therapy before ASCT) had delayed CD19+ cell reconstitution that persisted for at least 18 months after ASCT. No other differences in immune reconstitution based on lymphoma subtype were observed. Post-ASCT pembrolizumab maintenance therapy was associated with an elevation in circulating DCs (driven by higher levels of plasmacytoid and immature DCs) that persisted for the duration of pembrolizumab treatment, along with a significant reduction in PD-1+ T cells that persisted for 6 to 12 months after completion of pembrolizumab therapy. Despite the key role of T cells in mediating the effects of PD-1 blockade, pembrolizumab maintenance did not affect recovery of any T cell subsets. In an exploratory analysis, a higher baseline CD4+ terminal effector memory cell count (defined as CD3+CD4+CD45RA+CD62L-) was associated with inferior progression-free survival (PFS), but only among patients who received pembrolizumab maintenance (P = .003). As continuous variables, lower absolute levels of NK cells (P = .009), PD-1+ CD4+ T cells (P = .005), and PD-1+ CD8+ T cells (P = .005) before pembrolizumab initiation were each associated with a higher risk of grade 2+ irAEs. Our findings indicate that post-ACST pembrolizumab maintenance therapy is associated with a persistent elevation of circulating DCs, but its impact on the reconstitution of other immune cells in peripheral blood appears limited. Our study suggests that early features of post-ASCT immune reconstitution could be associated with PFS and the risk of irAE and warrant additional investigation. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc." @default.
• W3206425717 created "2021-10-25" @default.
• W3206425717 creator A5001243668 @default.
• W3206425717 creator A5003830250 @default.
• W3206425717 creator A5008718116 @default.
• W3206425717 creator A5015287155 @default.
• W3206425717 creator A5016570475 @default.
• W3206425717 creator A5019564077 @default.
• W3206425717 creator A5028590331 @default.
• W3206425717 creator A5029237145 @default.
• W3206425717 creator A5030302395 @default.
• W3206425717 creator A5030788778 @default.
• W3206425717 creator A5031525963 @default.
• W3206425717 creator A5037526878 @default.
• W3206425717 creator A5037613158 @default.
• W3206425717 creator A5045167741 @default.
• W3206425717 creator A5046770086 @default.
• W3206425717 creator A5049355235 @default.
• W3206425717 creator A5063755644 @default.
• W3206425717 creator A5065588144 @default.
• W3206425717 creator A5066824630 @default.
• W3206425717 creator A5071407925 @default.
• W3206425717 creator A5077617918 @default.
• W3206425717 creator A5077671733 @default.
• W3206425717 creator A5083104525 @default.
• W3206425717 creator A5085801543 @default.
• W3206425717 creator A5086268153 @default.
• W3206425717 creator A5088077600 @default.
• W3206425717 date "2022-01-01" @default.
• W3206425717 modified "2023-10-14" @default.
• W3206425717 title "Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma" @default.
• W3206425717 cites W1849671624 @default.
• W3206425717 cites W1997353354 @default.
• W3206425717 cites W2074546881 @default.
• W3206425717 cites W2128395874 @default.
• W3206425717 cites W2133201432 @default.
• W3206425717 cites W2141082026 @default.
• W3206425717 cites W2157717016 @default.
• W3206425717 cites W2166103269 @default.
• W3206425717 cites W2206276344 @default.
• W3206425717 cites W2397817666 @default.
• W3206425717 cites W2412725897 @default.
• W3206425717 cites W2473498748 @default.
• W3206425717 cites W2506616866 @default.
• W3206425717 cites W2530695400 @default.
• W3206425717 cites W2567998110 @default.
• W3206425717 cites W2582784681 @default.
• W3206425717 cites W2605810679 @default.
• W3206425717 cites W2609973112 @default.
• W3206425717 cites W2753945613 @default.
• W3206425717 cites W2786224778 @default.
• W3206425717 cites W2805486416 @default.
• W3206425717 cites W2895911012 @default.
• W3206425717 cites W2901759994 @default.
• W3206425717 cites W2907554401 @default.
• W3206425717 cites W2907929175 @default.
• W3206425717 cites W2909334052 @default.
• W3206425717 cites W2909590671 @default.
• W3206425717 cites W2932112746 @default.
• W3206425717 cites W2999252190 @default.
• W3206425717 cites W3011497962 @default.
• W3206425717 cites W3026270374 @default.
• W3206425717 cites W3047696352 @default.
• W3206425717 cites W3089064012 @default.
• W3206425717 cites W3090511595 @default.
• W3206425717 cites W3092987674 @default.
• W3206425717 cites W3105850195 @default.
• W3206425717 cites W3112167776 @default.
• W3206425717 cites W3120743663 @default.
• W3206425717 cites W3156424361 @default.
• W3206425717 doi "https://doi.org/10.1016/j.jtct.2021.10.010" @default.
• W3206425717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34670169" @default.
• W3206425717 hasPublicationYear "2022" @default.
• W3206425717 type Work @default.
• W3206425717 sameAs 3206425717 @default.
• W3206425717 citedByCount "7" @default.
• W3206425717 countsByYear W32064257172022 @default.
• W3206425717 countsByYear W32064257172023 @default.
• W3206425717 crossrefType "journal-article" @default.
• W3206425717 hasAuthorship W3206425717A5001243668 @default.
• W3206425717 hasAuthorship W3206425717A5003830250 @default.
• W3206425717 hasAuthorship W3206425717A5008718116 @default.
• W3206425717 hasAuthorship W3206425717A5015287155 @default.
• W3206425717 hasAuthorship W3206425717A5016570475 @default.
• W3206425717 hasAuthorship W3206425717A5019564077 @default.
• W3206425717 hasAuthorship W3206425717A5028590331 @default.
• W3206425717 hasAuthorship W3206425717A5029237145 @default.
• W3206425717 hasAuthorship W3206425717A5030302395 @default.
• W3206425717 hasAuthorship W3206425717A5030788778 @default.
• W3206425717 hasAuthorship W3206425717A5031525963 @default.
• W3206425717 hasAuthorship W3206425717A5037526878 @default.
• W3206425717 hasAuthorship W3206425717A5037613158 @default.
• W3206425717 hasAuthorship W3206425717A5045167741 @default.
• W3206425717 hasAuthorship W3206425717A5046770086 @default.
• W3206425717 hasAuthorship W3206425717A5049355235 @default.
• W3206425717 hasAuthorship W3206425717A5063755644 @default.
• W3206425717 hasAuthorship W3206425717A5065588144 @default.
• W3206425717 hasAuthorship W3206425717A5066824630 @default.

• next